Tumor treatment with gliotoxin derivatives

Details Tumor treatment with gliotoxin derivatives Tumor treatment with gliotoxin derivatives

2011-07-19

2011-07-19

Fetterolf, Brandon J (Department: 1628)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Heterocyclic carbon compounds containing a hetero ring...

C514S222800

Reexamination Certificate

active

07981878

ABSTRACT:
The present invention describes the use of Notch2 inhibitors for producing a medicament for the treatment of tumours, which tumours are characterized by ligand-independent Notch2 fragments.

REFERENCES:
patent: 2004/0101847 (2004-05-01), Freier et al.
patent: 2004/1001847 (2004-05-01), Freier et al.
patent: 2004/0137569 (2004-07-01), Chan et al.
patent: 0 163 475 (1985-12-01), None
patent: 0 926 242 (1999-06-01), None
patent: 61-277617 (1986-12-01), None
patent: 6220065 (1994-08-01), None
patent: 7227293 (1995-08-01), None
patent: WO 92/10198 (1992-06-01), None
patent: WO 2004/019921 (2004-03-01), None
Tompsett et al. Tuberculostatic activity of blood and urine from animals given gliotoxin. Cornell Medical Center, New York. Feb. 6, 1950.
Karon & Klyce. Effect of inhibition of inflammatory mediators on trauma-induced stromal edema. Investigative Ophthalmology & Visual Science, Jun. 2003, vol. 4, No. 6, pp. 2507-2510.
Vigushin et al. Gliotoxin is a dual inhibitor of farnesyltransferase and geranylgeranyltransferase I with antitumor activity against breast cancer in vivo. Medical Oncology, vol. 21, No. 1, 21-30, 2004.
Tiwari et al. Among circulating hematopoietic cells, B-CLL uniquely expresses functional EPAC1, but EPAC1-mediated Rap1 activation does not account for PDE4 inhibitor-induced apoptosis. Blood, 2004, 103: 2661-2667.
Marzo et al. Farnesyltransferase inhibitor BMS-214662 induces apoptosis in B-cell chronic lymphocytic leukemia cells. Leukemia, 2004, 18, 1599-1604.
Sutton et al. Evidence that gliotoxin enhances lymphocyte activation and induces apoptosis by effects on cyclic AMP levels. Biochemical Pharmacology, vol. 50, No. 12, pp. 2009-2014,1995.
Gaiger et al. Novel molecular diagnostic and therapeutic targets in chronic lymphocytic leukaemia. European Journal of Clinical Investigation, 34 (Suppl. 2), 25-30, 2004.
Cuevas et al., “Meningioma transcript profiles reveal deregulated Notch signaling pathway,”Cancer Res., 65:5070-5075, 2005.
Fan et al., “Notchl and notch2 have opposite effects on embryonal brain tumor growth,”Cancer Res., 64:7787-7793, 2004.
Gardiner et al., “The epipolythiodioxopiperazine (ETP) class of fungal toxins: distribution, mode of action, functions and biosynthesis,”Microbiology, 151:1021-1032, 2005.
Garnis et al., “Involvement of multiple developmental genes on chromosome 1p in lung tumorigenesis,”Hum. Mol. Gen., 14:475-82, 2004.
Hoek et al., “Expression profiling reveals novel pathways in the transformation of melanocytes to melanomas,”Cancer Res., 64:5270-82, 2004.
Hubmann et al., “Involvement of PKC-delta in the regulation of Notch2 ni B-CLL,”Blood, 106(11):Abstract 4990, 2005.
Hubmann et al., “Notch2 is involved in the overexpression of CD23 in B-cell chronic lymphocytic leukemia,”Blood, 99:3742-7, 2002.
Hurne et al., “Inactivation of rabbit muscle creatine kinase by reversible formation of an internal disulfide bond induced by the fungal toxin gliotoxin,”JBC, 275:25202-6, 2000.
Jansen et al., “bcl-2 antisense therapy chemosensitizes human melanoma in SCID mice,”Nat. Med., 4:232-234, 1998.
Jehn et al., “Cutting edge: protective effects of notch-1 on TCR-induced apoptosis,”JI, 162:635-8, 1999.
Jundt et al., “Novel gamma-secretase inhibitor DAPT blocks activated notch signaling and controls tumor cell growth in Hodgkin and anaplastic large cell lymphoma,”Blood, 100(11):Abstract 594, 2002.
Knowles et al., “Human hepatocellular carcinoma cell lines secrete the major plasma proteins and hepatitis B surface antigen,”Science, 209:497-499, 1980.
Kweon et al., “Gliotoxin-mediated apoptosis of activated human hepatic stellate cells,”J. Hepato., 39:38-42, 2003.
Lauring and Overbaugh, “Evidence that an IRES within the Notch2 coding region can direct expression of a nuclear form of the protein,”Mol. Cell, 6:939-45, 2000.
Lee et al., “Anti-angiogenic activities of gliotoxin and its methylthioderivative, fungal metabolites,”Arch. Pharm. Res., 24:397-401, 2001.
Lee et al., “Notch 2-positive progenitors with the intrinsic ability to give rise to pancreatic ductal cells,”Lab. Invest., 85:1003-12, 2005.
Lehmann et al., “MUC18, a marker of tumor progression in human melanoma, shows sequence similarity to the neural cell adhesion molecules of the immunoglobulin superfamily,”Proc. Natl. Acad. Sci. USA, 86:9891-9895, 1989.
Leong and Karsan, “Recent insights into the role of Notch signaling in tumorigenesis,”Blood, 107:2223-33, 2006.
Lewis et al., “Detection of gliotoxin in experimental and human aspergillosis,”Infect. and Immun., 73:635-7, 2005.
Lieber et al., “Establishment of a continuous tumor-cell line (panc-1) from a human carcinoma of the exocrine pancreas,”Int. J. Cancer, 15:741-747, 1975.
Lin et al., “Conversion of Bcl-2 from protector to killer by interaction with nuclear orphan receptor Nur77/TR3,”Cell, 116:527-40, 2004.
Maillard et al., “Mastermind critically regulates Notch-mediated lymphoid cell fate decisions,”Blood, 104:1696-1702, 2004.
Martin et al., “Quantitative proteomic analysis of proteins released by neoplastic prostate epithelium,”Cancer Res., 64:347-55, 2004.
Massi et al., “Evidence for differential expression of Notch receptors and their ligands in melanocytic nevi and cutaneous malignant melanoma,”Modern Pathology, 19:246-254, 2006.
Miele, “Notch signaling,”Clin. Cancer Res., 12:1074-9, 2006.
Müllbacher et al., “Selective resistance of bone marrow-derived hemopoietic progenitor cells to gliotoxin,”PNAS, 84:3822-5, 1987.
Nickoloff et al., “Notch signaling as a therapeutic target in cancer: a new approach to the development of cell fate modifying agents,”Oncogene, 22:6598-6608, 2003.
Orr et al., “Mechanism of action of the antifibrogenic compound gliotoxin in rat liver cells,”Hepatology, 40:232, 2004.
Paris et al., “Inhibition of angiogenesis and tumor growth by βand γ-secretase inhibitors,”European Journal of Pharmacology, 514:1-15, 2005.
Park et al., “Characterization of cell lines established from human hepatocellular carcinoma,”Int. J. Cancer, 62:276-282, 1995.
Parr et al., “The possible correlation of Notch-1 and Notch-2 with clinical outcome and tumour clinicopathological parameters in human breast cancer,”Int. J. Mol. Med., 14:779-786, 2004.
Radtke and Raj, “The role of Notch in tumorigenesis: oncogene or tumour suppressor?,”Nat. Rev. Cancer, 3:756-67, 2003.
Santagata et al., “JAGGED1 expression is associated with prostate cancer metastasis and recurrence,”Cancer Res., 64:6854-6857, 2004.
Schwarzmeier et al., “Regulation of CD23 expression by Notch2 in B-cell chronic lymphocytic leukemia,”Leuk. Lymphoma, 46:157-165, 2005.
Sutton et al., “In vivo immunosuppressive activity of gliotoxin, a metabolite produced by human pathogenic fungi,”Infect. and Immun., 62:1192-8, 1994.
Vigushin et al., “Gliotoxin is a dual inhibitor of farnesyltransferase and geranylgeranyltransferase I with antitumor activity against breast cancer in vivo,”Med. Oncol., 21:21-30, 2004.
Yunis et al., “Human pancreatic carcinoma (MIA PaCa-2) in continuous culture: sensitivity to asparaginase,”Int. J. Cancer, 19:128-135, 1977.
Zhang et al., “Notch signaling pathway contributes to osteosarcoma growth, tumorigenesis and metastasis,”AACR Meeting Abstracts, 2006.

Affiliated with

Also associated with

Rating

Tumor treatment with gliotoxin derivatives does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Tumor treatment with gliotoxin derivatives, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Tumor treatment with gliotoxin derivatives will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2717523